TABLE 2.

Fasting levels of plasma markers before and after 48-h infusion of saline or intralipid plus heparin*

		SAL	IH	IH + PBA	PBA
Glucose, mmol/L	Preinfusion	5.23 ± 0.14	5.03 ± 0.14	5.09 ± 0.17	5.13 ± 0.15
	Preclamp	5.23 ± 0.15	5.43 ± 0.22	5.50 ± 0.34	5.29 ± 0.22
Insulin, pmol/L	Preinfusion	107.10 ± 15.67	86.40 ± 12.41	81.47 ± 11.36	83.11 ± 7.02
	Preclamp	93.40 ± 11.33	102.69 ± 11.15	78.24 ± 5.33	87.67 ± 18.83
C-peptide, nmol/L	Preinfusion	0.75 ± 0.12	0.66 ± 0.08	0.59 ± 0.08	0.59 ± 0.09
	Preclamp	0.63 ± 0.10	0.77 ± 0.12	0.74 ± 0.13	0.68 ± 0.08
Triglyceride, mmol/L	Preinfusion	1.60 ± 0.46	1.28 ± 0.19	1.47 ± 0.32	1.40 ± 0.36
	Preclamp	1.58 ± 0.24	2.63 ± 0.36†‡§	3.04 ± 0.44†‡§	1.63 ± 0.26
Free fatty acid, mmol/L	Preinfusion	0.42 ± 0.08	0.43 ± 0.06	0.48 ± 0.07	0.50 ± 0.05
	Preclamp	0.38 ± 0.05	0.74 ± 0.04†‡§	0.73 ± 0.07†‡§	0.38 ± 0.05

Data are means ± SE; N = 8.

Clamps were performed on subjects in four randomized visits after a 48-h SAL infusion; a 48-h IH infusion; 2-week oral PBA (7.5 g/day), followed by a 48-h IH infusion; or 2-week oral PBA, followed by a 48-h SAL infusion. Preinfusion, before start of SAL or IH infusion. Preclamp, 48-h after start of SAL or IH infusion and before start of the clamp.

†P, 0.05 vs. SAL;

‡P, 0.05 vs. PBA;

§P, 0.05 vs. preinfusion.